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Objectives: To establish the relationship between quality of life (QOL) index scores and clinical indicators of lower limb ischemia.
Methods: One hundred seventy-eight patients (108 men, median age 70 years) with femoropopliteal lesions suitable for
angioplasty were recruited. Assessments were performed prior to and at 1, 3, 6, and 12 months following intervention
(angioplasty and/or supervised exercise program). Clinical indicators of lower limb ischemia (treadmill walking
distances, ankle pressures), generic (SF36, EuroQol), and disease-specific (Kings College VascuQol) quality of life
questionnaires were analyzed. Correlation analysis was performed for index scores (SF-6D, EQ-5D, VascuQol) and
individual domain scores using nonparametric tests.
Results: All clinical indicators of lower limb ischemia and quality of life index scores showed a statistically significant improvement
as result of intervention (Friedman test, P < .001). Both generic QOL index scores (SF-6D, EQ-5D) showed moderate but
statistically significant correlation (Spearman’s rank correlation, P < .001) with treadmill walking distances (SF-6D r  0.533,
EQ-5D r0.500) andweakbut significant correlation to resting andpostexercise ankle-brachial pressure index (SF-6D r0.253,
EuroQol r 0.214). Disease-specific index scores (VascuQol) showed similar moderate correlation to treadmill walking distances
(r 0.584, P< .001) and weak but statistically significant correlation with resting and postexercise ABPI (r 0.377, P< .001).
All index scores showed strong and statistically significant (P< .001) correlationwithpatient-reportedwalkingdistance (SF-6D r
0.604, EQ-5D r  0.511, VascuQol r  0.769). All domains of SF36 showed similar correlation with clinical indicators except
general health. The strongest correlationwas seenwith treadmill walking distances in the domains of physical function (r 0.538)
and bodily pain (r 0.524).
Conclusion: All generic and disease-specific QOL scores show statistically significant improvement with angioplasty
and/or supervised exercise in patients with claudication due to femoropopliteal atherosclerosis. However, the degree of
improvement seen in clinical indicators of lower limb ischemia is not reflected in these scores. These findings support the
use of composite outcome measures with mandatory, independent assessment of QOL as an independent outcome
measure in intervention studies in these patients. ( J Vasc Surg 2010;52:77-84.)Intermittent claudication (IC) is a common condition
affecting 5% of the population over 55 years of age in
developed countries.1 Despite its benign course, it confers
significant quality of life (QOL) limitations.2 In recent
years, QOL outcomes have been reported regularly in
claudication trials. A number of generic and disease-specific
QOL tools have been tested and validated for use in this
particular population. Most commonly used tools are the
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doi:10.1016/j.jvs.2010.01.085Medical Outcomes Study Short Form 36 (SF-36) and the
EuroQol (EQ-5D) questionnaires for generic,3 and King’s
College Hospital’s Vascular Quality of Life (VascuQol)
questionnaire for disease-specific QOL assessment.4 Fur-
thermore, economic analyses utilize generic QOL index
scores, for estimation of health utility gains and quality-
adjusted life year (QALY) calculations. EQ-5D has been
used frequently in such studies; however, more recently the
Short Form 6-D (SF-6D) preference-based index derived
from SF-36 has been increasingly used in cost utility anal-
yses. There is a relative dearth of studies evaluating the
relationship between these index scores and the degree of
improvement in clinical indicators as a result of intervention
in claudicants. The aim of this study was to investigate this
relationship using both generic and disease-specific tools.
METHODS
This prospective observational study was approved by a
local research ethics committee and was performed in an
academic vascular surgical unit in a tertiary care university
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were recruited from an ongoing randomized controlled
trial comparing percutaneous transluminal angioplasty
(PTA), supervised exercise program (SEP), and combined
treatment (PTA SEP) over a 5-year period from Septem-
ber 2002 to April 2007. Patients with critical limb ischemia
were excluded. The inclusion and exclusion criteria are
given in Table I. Informed consent was obtained from all
participating patients.
Interventions
All PTAs were performed by a vascular consultant
radiologist according to standard protocol. Stents were not
used in any patients. Patients in SEP group attended three
sessions of exercise every week for 12 consecutive weeks.
Each session comprised gentle warm-up exercises followed
by six exercise stations including exercise bicycle, knee
extensions, double-heel raises, single-leg presses, walking
up and down a 6-inch step, and elbow flexion and extension
using dumbbells in a closed circuit format. Each station
lasted for 2 minutes with 2 minutes of brisk walking on a
flat surface in between the stations. The sessions ended with
warm down exercises and gentle stretches. All patients
completed one full circuit for 6 weeks followed by an
additional station every week, thus completing two full
circuits at 12 weeks; 85% attendance was required for
successful completion of SEP. Patients in the combined
treatment group started SEP in the week following angio-
plasty. This SEP regimen was opted for its established
clinical and cost effectiveness.5
Assessments
All patients were assessed prior to and at 1, 3, 6, and 12
months after intervention. Patients underwent fixed-load
treadmill testing (2.5 km/h at 10 degree incline) for 5
minutes at each visit. Clinical indicators of lower limb
ischemia including pre- and postexercise ankle-brachial
pressure index (ABPI), intermittent claudication distance
Table I. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
● Symptomatic unilateral IC
● Femoropopliteal lesion
amenable to angioplasty
(duplex/angiogram)
● Symptoms stable after 3 mo
on best medical treatment
(risk factor modification,
antiplatelets, statins)
● Patient fit to undertake
supervised exercise
program
● Critical ischemia
● Severe limitation to physical
activity due to systemic disease
(eg, heart failure, severe
arthritis) not including PAD
● Inability to tolerate treadmill
testing
● Significant ischemic changes in
ECG trace during treadmill
testing
● Ipsilateral surgery (PAD or
otherwise) in previous 6 mo
● Ipsilateral angioplasty in
previous 6 mo
ECG, Electrocardiogram; IC, intermittent claudication; PAD, peripheral
arterial occlusive disease.(ICD), and maximal walking distance (MWD) were re-corded. In addition, patients were asked to complete two
generic (EQ-5D and SF-36) and one disease-specific
(VascuQol) QOL questionnaire. Questionnaires were ad-
ministered in random order, reviewed immediately after
submission and returned to the patients to fill in themissing
responses, if any, prior to conclusion of the follow-up visit
to ensure completion of data.
SF-36
SF-36 is a generic QOL tool containing 36 questions
producing a health profile in eight different domains—
namely physical function, role limitation due to physical
state, bodily pain, general health, vitality, social function,
role limitation due to emotional state, and mental health.6
For each domain, the scores are coded, summed, and
transformed on a scale from 0 (worst possible health) to
100 (best possible health). This instrument is acceptable,
reliable, and valid for use in claudicants.3
SF-6D
SF-6D is a preference-based measure of health derived
from SF-36, which was developed for use in economic
evaluation.7 It utilizes 10 questions from SF-36 and classi-
fies them into six health domains—namely physical func-
tion, role limitation, social function, pain, mental health,
and vitality. The health state defined by these domains is
transformed to a linear scale ranging from 0.296 (worst
possible health) to 1 (best possible health) using standard
gamble technique. A matrix for direct calculation of SF-6D
index score from SF-36 domain scores has also been devel-
oped.8 Since its development, SF-6D has been tested and
validated for use in various patient groups9 and is currently
in use in many health economic studies.
EuroQol
EuroQol consists of two parts. The first part utilizes
five questions representing five domains (EQ-5D) namely
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression; with three possible responses to each,
which are analyzed using a time trade off (TTO) matrix
yielding TTO index score. The second part consists of a
visual analogue scale (VAS) used to rate health from 0
(worst imaginable health) to 100 (best imaginable health)
and is reported directly as VAS index score.10,11 EQ-5Dhas
been tested and validated for use in claudicants.3
VascuQol
King’s College VascuQol is a disease-specific question-
naire for use in claudicants, which comprises 25 questions
with seven possible responses to each.12 The questions are
grouped together into five domains—namely activity,
symptoms, pain, emotional, and social. The domain scores
are calculated by dividing the total sum of responses by
total number of questions in each domain. The index score
is the arithmetic average of all the responses. The outcomes
can be reported in the form of profile for each domain
and/or an index score. This is a sensitive, reliable, and
validated instrument.4
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The data were analyzed using SPSS 15.0 (SPSS Corpo-
ration, Chicago, Ill) software. Basic demographics and
comorbidities were recorded for all patients. All variables
were checked for normality using histograms and normality
tests (Shapiro-Wilk). Continuous variables were analyzed
using nonparametric tests for paired (Friedman, Wilcoxon)
and unpaired (Kruskal-Wallis one-way analysis of variance
[ANOVA], Mann-Whitney) data. Adjustment was made
for multiple testing by dividing the alpha (0.05) by the total
number of statistical tests performed, and P  .008 was
considered significant. Nonparametric correlation (Spear-
man’s rank) analysis was performed initially for QOL scores
(index and domain) and clinical indicators. Linear time
plots were constructed for all clinical indicators and
index scores, and area under the curve (AUC) was calcu-
lated. Sensitivity to change over time was assessed by
performing correlation analysis using AUC for clinical
indicators and index scores. We used recommended la-
bels to describe the strength of association as very weak
(r  0.00-0.19), weak (r  0.20-0.39), moderate (r 
0.40-0.59), strong (r 0.60-0.79), and very strong (r
0.80-1.00), respectively.13
RESULTS
One hundred seventy-eight patients (108 males, me-
dian age 70 years) were recruited. Attendance rate for
follow-up assessments was 88% across all time points. Basic
demographics for study participants are given in Table II.
Clinical indicators (Table III)
All clinical indicators showed statistically significant
improvement as a result of intervention at all time points
(Friedman test, P  .001) and final endpoint (Wilcoxon
signed rank test, P  .001). At the final endpoint (12
months following intervention), pre- and postexercise
ABPI showed a median improvement of 19.4% and 31.2%,
respectively; while ICD, MWD, and PRWD showed a far
greater median improvement of 96.5%, 43%, and 200%,
Table II. Basic demographics of the study participants
Variable Median/N IQR/%
Age (y) 70 63-75
Male gender 108 60.7
Diabetes 25 14.0
Hypertension 114 64.0
Hypercholesterolemia 135 75.8
Smoker 55 30.9
Treatment
PTA 60 33.7
SEP 60 33.7
PTA  SEP 58 32.6
IQR, Interquartile range; PTA, percutaneous transluminal angioplasty; SEP,
supervised exercise program.
Continuous variables are represented as median with IQR, while categorical
variables are described as total number (N) with percentage.respectively.QOL outcomes (Table IV)
All QOL index scores also showed a statistically signif-
icant improvement as a result of intervention at all time
points (Friedman test, P  .005) as well as final end point
(Wilcoxon signed-rank test, P .001) except the EuroQol
VAS index. At 12months, the median percentage improve-
ment seen in SF-6D, EuroQol TTO and VascuQol indices
was 6.2%, 20.8% and 27.5%, respectively. All SF-36 domain
scores showed a statistically significant improvement except
vitality and general health.
Correlation analysis
QOL index scores (Table V). Correlation analysis
showed a very weak or weak correlation of QOL index
scores with resting and postexercise ABPI. Moderate cor-
relation was seen between the index scores and objectively
measures walking distances (ICD and MWD), while a
moderate to strong correlation was seen with the patient-
reported walking distance. In all categories, the disease-
specific scores (VascuQol) reported a higher strength of
correlation compared with the generic index scores. All
correlations were statistically significant.
Generic QOL domains (Table V). The SF-36 do-
main scores showed very weak to weak correlation with all
clinical indicators except the domains of physical function,
bodily pain, and vitality where a moderate correlation was
seen with the walking distances.
Change over time (Figs 1-5, Table VI). Correlation
of AUC calculated from linear time plots showed strong
correlation between QOL index scores and ICD, moderate
correlation between QOL indices and MWD, and moder-
ate to strong correlation between these indices and PRWD.
The correlation between the AUC for resting and postex-
ercise ABPI and QOL indices remained weak. All correla-
tions were statistically significant (P  .001) except the
correlations of SF-6D and EQ-5D TTO with postexercise
ABPI.
DISCUSSION
There is strong evidence in the literature to suggest that
patients with peripheral arterial occlusive disease (PAD)
score consistently lower on generic QOL questionnaires in
domain and summary scores compared with healthy con-
trols after adjustment for age, gender, social class, body
mass index, and smoking.14-19 Although these generic
questionnaires are not as good as disease-specific tools,4,20,21
they demonstrate sensitivity to change as a result of
intervention in these patients, regardless of the type of
intervention.22-24 Moreover, a small number of previous
studies have demonstrated the correlation between QOL
and clinical indicators of lower limb ischemia to be, at best,
moderate,25-27 with the performance of disease-specific
being superior to generic instruments.4,24,28 However, un-
like most of these studies, we have comparedmultiple index
scores with clinical indicators at multiple time points prior
to and following intervention giving a more appropriate
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this change in clinical indicators and QOL indices by cal-
culating AUC from linear time plots, followed by the
correlation between these AUC values to assess the sensi-
tivity to change of the QOL indices has not been reported
previously. Our study has shown some interesting findings
Table III. Clinical indicators of lower limb ischemia (pre-
Variable Baseline median
Resting ABPI 0.68 (0.55-0.8
Postexercise ABPI 0.41 (0.25-0.6
Intermittent claudication distance (meters) 41.40 (23.50-68
Maximal walking distance (meters) 82.80 (53.71-13
Patient-reported walking distance (meters) 150.0 (55.00-22
ABPI, Ankle-brachial pressure index; IQR, interquartile range.
Values are quoted as median with IQR.
aFriedman test.
Table IV. Quality of life results (pre- and postintervention
Variable Baseline median (IQR)
SF-6D 0.66 (0.57-0.72)
EQ-5D TTO 0.69 (0.20-0.73)
EQ-5D VAS 65.00 (50.00-80.00)
VascuQol 4.14 (3.20-5.12)
SF-36 physical function (PF) 35.00 (20.00-55.00)
SF-36 role physical (RP) 25.00 (0.00-75.00)
SF-36 bodily pain (BP) 41.50 (31.00-70.00)
SF-36 general health (GH) 57.00 (42.00-72.00)
SF-36 vitality (VT) 50.00 (35.00-65.00)
SF-36 social function (SF) 75.00 (50.00-87.50)
SF-36 role emotional (RE) 66.67 (0.00-100.00)
SF-36 mental health (MH) 72.00 (56.00-88.00)
EQ-5D TTO, Euroqol Time Trade Off; EQ-5D VAS, EuroQol Visual Analo
Values are quoted as median with IQR.
aFriedman test.
Table V. Spearman’s rank correlation between clinical ind
Resting ABPI Postex
SF-6D 0.253a
EQ-5D TTO 0.214a
EQ-5D VAS 0.189a
VascuQol 0.377a
Physical function (PF) 0.248a
Role physical (RP) 0.230a
Bodily pain (BP) 0.205a
General health (GH) 0.129a
Vitality (VT) 0.157a
Social function (SF) 0.195a
Role emotional (RE) 0.236a
Mental health (MH) 0.123a
ABPI, Ankle-brachial pressure index; EQ-5D TTO, EuroQol Time Trade O
Score.
All moderate to strong correlations are identified in bold.
aP .001.that are discussed individually as follows:Clinical indicators
The significant improvement in clinical indicators as a
result of intervention was similar to that described in pre-
vious studies24,28 with relatively small improvement in
ABPI and larger improvement in treadmill walking dis-
postintervention)
)
Postintervention median (IQR)
Month 1 Month 3
0.89 (0.71-1.00) 0.85 (0.69-1.00)
0.61 (0.38-0.86) 0.61 (0.40-0.86)
64.08 (34.50-149.17) 82.80 (46.59-214.30)
117.39 (72.00-215.00) 135.10 (83.55-215.00)
400 (200.00-1000.00) 600.00 (200.00-1000.00)
Postintervention median (IQR)
Month 1 Month 3
0.72 (0.64-0.80) 0.71 (0.62-0.81)
0.71 (0.62-0.78) 0.69 (0.62-0.80)
70.00 (60.00-80.00) 70.00 (55.00-81.00)
5.52 (4.41-6.32) 5.56 (4.49-6.34)
55.00 (35.00-76.59) 57.73 (35.00-75.00)
50.00 (0.00-100.00) 50.00 (0.00-100.00)
61.00 (41.00-83.00) 61.50 (41.00-80.00)
60.00 (41.50-72.00) 57.00 (41.50-72.00)
55.00 (40.00-70.00) 55.00 (40.00-70.00)
87.50 (62.50-100.00) 75.00 (50.00-100.00)
100.00 (33.30-100.00) 100.00 (33.30-100.00)
76.00 (60.00-92.00) 80.00 (64.00-92.00)
cale; IQR, interquartile range; SF-6D, Short Form 6D Index Score.
rs and QOL index and SF-36 domain scores
ABPI ICD MWD PRWD
a 0.533a 0.517a 0.604a
a 0.500a 0.394a 0.511a
a 0.449a 0.402a 0.407a
a 0.584a 0.546a 0.769a
a 0.565a 0.542a 0.654a
a 0.358a 0.336a 0.456a
a 0.474a 0.416a 0.527a
0.301a 0.271a 0.363a
a 0.460a 0.411a 0.426a
a 0.372a 0.401a 0.465a
a 0.344a 0.345a 0.396a
0.303a 0.342a 0.315a
-5D VAS, EuroQol Visual Analogue Scale; SF-6D, Short Form 6D Indexand
(IQR
3)
1)
.32)
7.25)
5.00))
gue Sicato
ercise
0.205
0.145
0.151
0.336
0.242
0.204
0.178
0.093
0.104
0.131
0.159
0.091
ff; EQtances. Interestingly, PRWD has been demonstrated to
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its significant improvement with intervention,24 thus, its
value as a clinical outcome measure has been questioned.
However, our study demonstrated a relatively strong cor-
relation between PRWD and QOL indices. This can be
partially explained by the subjective nature of both these
outcome measures, and the strength of correlation with
QOL indices seen in direct and AUC analyses makes a
strong argument for its continued use as a patient-reported
outcome measure along with the clinical indicators in this
population.
Treadmill walking distances have always been strongly
associated with improvement in QOL indicators. The
strongest relationship in previous studies has been between
QOL and MWD. Interestingly, in our study, correlation
between all index scores was stronger with treadmill ICD
than with MWD. This difference was even more pro-
nounced in the AUC correlation where ICD showed a
strong correlation with all QOL indicators, while MWD
only showed a moderate correlation. There are two poten-
tial explanations for this: first, the degree of improvement
seen in ICD was far greater than MWD, and second, the
MWD was capped at 5 minutes of treadmill time (215
meters) perhaps resulting in a significant “ceiling effect”.
Table III. Continued.
Postintervention median (IQR)
Month 6
0.83 (0.70-1.00)
0.60 (0.35-0.81)
94.75 (47.80-215.00) 9
155.45 (90.15-215.00) 21
505.00 (200.00-1450.00) 44
Table IV. Continued.
Postintervention median (IQR)
Month 6
0.70 (0.60-0.80)
0.71 (0.54-0.80)
68.00 (55.00-80.00) 7
5.44 (4.13-6.15)
55.00 (28.75-75.00) 5
50.00 (0.00-100.00) 2
56.50 (41.00-74.00) 5
57.00 (40.00-72.75) 5
50.00 (35.00-70.00) 5
75.00 (50.00-100.00) 7
100.00 (33.30-100.00) 8
76.00 (60.00-92.00) 8This limitation could be overcome in future studies byincreasing the treadmill cap time or walking the patient to
absolute claudication. The latter, however, remains a diffi-
cult option considering the time constraints in modern
clinical settings.
The association between ankle pressures and QOL
indices in previous studies has always been a poor
one,20,27,30 and our study reconfirms these findings. How-
ever, previous studies mainly analyzed ABPI as a single
variable, with only one study reporting the correlation
separately with pre- and postexercise ABPI, but this was
only performed for disease-specific instruments.4 We have
explored the relationship further using both generic and
disease-specific instruments. The correlation between
QOL and resting ABPI wasmarginally superior to that with
postexercise ABPI. This highlights the individual impor-
tance of both ABPI and QOL as outcome measures, in
order to document hemodynamic and clinical effectiveness
respectively, neither of which can be assumed from changes
in the other.
QOL indicator
Improvement seen in QOL indicators was smaller than
that seen in clinical indicators, which is consistent with
P valueaMonth 12
(0.69-1.00) .001
(0.38-0.89) .001
(56.20-215.00) .001
(90.90-215.00) .001
(195.00-1600.00) .001
P valueaMonth 12
(0.59-0.80) .001
(0.62-0.80) .001
(50.00-80.00) .018
(3.96-6.23) .001
(30.00-80.00) .001
(0.00-100.00) .001
(41.00-83.00) .001
(39.25-72.00) .128
(40.00-65.00) .004
(50.00-100.00) .001
(0.00-100.00) .001
(60.00-88.00) .0010.88
0.63
8.00
5.00
0.000.70
0.69
0.00
5.28
0.00
5.00
4.00
5.00
0.00
5.00
3.35
0.00previous evidence.22 The disease-specific VascuQol dem-
reported walking distance.
Qol Time Trade Off; SF-6D, Short Form 6D Index Score.
under the curve; EQ-5DVAS,EuroQol Visual Analogue Scale.
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the generic QOL instruments.4
Interestingly, although SF-6D showed the smallest im-
provement as a result of intervention, it demonstrated a
better correlation with all clinical indicators than the EQ-
5D. This has been seen in previous studies where SF-6D
scores have shown a consistently better correlation compared
with EQ-5D in different clinical circumstances.9,31,32 This
makes a strong argument for use of SF-6D in this particular
patient group as generic QOL index. Furthermore, it
showed the strongest relationship with MWD in the AUC
analysis, even superior to the disease-specific VascuQol,
demonstrating a closer representation of change over time
in this particular parameter. This is highly significant as
MWD is known to correlate strongly with QOL measure-
ments.26,27 The EQ-5D TTO index was recommended as
the European standard for generic QOL measurement in
patients with intermittent claudication.3 EQ-5D TTO and
0.88
0.830.85
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0.68
0.63
0.600.610.61
0.41
0
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0.7
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1
Baseline Month 1 Month 3 Month 6 Month 12
Resng ABPI Post Exercise ABPI
AUC = 0.85 
AUC = 0.65 
Fig 1. This figure demonstrates the change over time for resting
and postexercise ABPI. The upper limit for follow-up was 1 year
posttreatment. ABPI, Ankle-brachial pressure index; AUC, area
under the curve.
98.0094.75
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135.10
82.80
0
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AUC = 84.78 
Fig 2. This figure demonstrates the change over time for tread-
mill walking distances. The upper limit for follow-up was 1 year
posttreatment. AUC, Area under the curve; ICD, intermittent
claudication distance; MWD, maximum walking distance.VAS both showed relatively weaker correlation compared440.00
505.00
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400.00
600.00
0
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300
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Baseline Month 1 Month 3 Month 6 Month 12
PRWD
AUC = 625.00
Fig 3. This figure demonstrates the change over time for patient-
reported walking distance. The upper limit for follow-upwas 1 year
posttreatment. AUC, Area under the curve; PRWD, patient-0.700.70
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Fig 4. This figure demonstrates the change over time for generic
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70.0068.0070.0070.0065.00
5.44
5.565.524.14
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Baseline Month 1 Month 3 Month 6 Month 12
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AUC = 68.45
AUC = 5.26
Fig 5. This figure demonstrates the change over time for generic Eu-
roqol visual analogue score anddisease-specificKing’sCollegeVascuqol.
The upper limit for follow-up was 1 year posttreatment. AUC, Area
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tionship changed considerably in AUC analysis, where
EQ-5D TTO showed a stronger correlation with ICD
compared with SF-6D. Furthermore, the strength of cor-
relation increased considerably with all clinical indicators.
Based on these findings, we can imply that although
EQ-5D TTO score correlates weakly with clinical indica-
tors at individual points in time, its representation of
change over time is similar and comparable with SF-6D.
ED-5D VAS also demonstrated similar but relatively
weaker correlations. The VascuQol has consistently shown
superior correlation compared with both the SF-6D and
EQ-5D with all clinical indicators except MWD in AUC
correlation analysis. Understandably, this is due to the
disease-specific nature of the questionnaire. Again, this is
consistent with the evidence reported in the previous stud-
ies.12,26
This study has several limitations. First, the study only
included patients with claudication due to femoropopliteal
disease, which represents only 25% to 31%33,34 of the
disease population and second, all patients with critical limb
ischemia were excluded.
The implications of this study are potentially profound.
Economic analyses utilize QOL indices for calculation of
QALYs to estimate utility gains.7 QALYs provide the
means to compare different types of interventions for allo-
cation of resources in health care systems.35 There is con-
siderable variability in sensitivity to change between the
indices used for QALY derivation, and they demonstrate
significantly less improvement compared with the clinical
parameters. Consequently, this is reflected in QALYs with
underestimation of the true benefit gained as a result of
intervention in this patient population. This is highly sig-
nificant in organizations where funding allocations utilize
these parameters. In addition, respected advisory agencies
(eg, National Institute of Health and Clinical Excellence)
utilize these parameters for the economic analysis in final
stages of health technology assessments, and insurance
institutions utilize these tools to calculate cost per QALY
gained for treatment assessments. Hence, underestimation
of effect can actually result in higher cost per QALY, thus
making these treatments more expensive, and less attrac-
Table VI. Spearman’s rank correlation between area unde
scores
Resting ABPI Postexercis
SF-6D 0.243a 0.198
EQ-5D TTO 0.326a 0.217
EQ-5D VAS 0.333a 0.250
VascuQol 0.388a 0.349
ABPI, Ankle-brachial pressure index; EQ-5D TTO, EuroQol Time Trade O
distance; MWD, maximum walking distance; PRWD, patient-reported walk
All moderate to strong correlations are identified in bold.
aP .001.tive, for health care providers and patients. Therefore,perhaps composite outcome measures, incorporating clin-
ical indicators along with sensitive disease-specific QOL
indices should be used for estimation of health benefit gain
in these situations.
CONCLUSION
QOL index scores provide an appropriate tool for
independent outcome reporting following intervention in
claudicants. The correlation between these indices and the
clinical indicators is insufficiently close to assume changes
in onemirror changes in the other, and both are essential to
provide an appropriate representation of change with treat-
ment. The disease-specific VascuQol index appears to cor-
relate more closely than generic indices with changes in
clinical indices of lower limb ischemia with treatment.
Furthermore, the use SF-6D and EQ-5D in economic
analyses may give an underestimation of the true value, and
VascuQol may be more appropriate for such estimations in
this particular disease population.
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